- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01943422
Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma (12-107)
Dose-seeking and Efficacy Study of the Combination of the BRAF Inhibitor Vemurafenib and High-dose Interferon Alfa-2b for Therapy of Advanced Melanoma
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
- Dose-selection and dose-expansion study of combination therapy with high-dose interferon alfa-2b and vemurafenib.
- Vemurafenib at standard dosing with a 2 week lead-in period to exploit potential immunomodulatory effects. Concurrent HDI following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.
- Modified Storer's "up and down" dose escalation schema using 3 fixed dose levels for HDI and a fixed sample size that allows efficient identification of recommended phase II dose.
- 36-63 patients will be enrolled depending on toxicity parameters. oIn the dose-selection portion, 3 patients will be enrolled per dose level, starting from the lowest dose level. Enrollment will occur serially allowing for the observation of toxicity during the observation period.
oIterative enrollment of up to 3 subjects per cohort will be continued until a total of 30 evaluable subjects have been enrolled.
oThe dose level at which the RLT rate is the closest to 1/3 will be considered as RP2D.
oDuring the dose-expansion portion of the trial, depending on the number of patients treated at RP2D during the dose-selection portion, additional patients may be enrolled - the accrual target is 36 patients treated at RP2D.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15232
- Hillman Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patients must have a written informed consent.
- 18 years of age.
- Patients must have histologically confirmed recurrent stage III or stage IV melanoma (AJCC 7th edition classification).
- BRAF V600E and V600K mutated
- Cutaneous squamous cell carcinomas (SCC) lesions identified at baseline must be excised. Adequate wound healing is required prior to study entry.
- Patients must have measurable disease as defined by the Response Evaluation Criteria in Solid Tumors v1.1.
Patients must have adequate hematologic, renal, and liver function:
- WBC ≥ 3,000/mm3
- ANC ≥ 1500
- Hb ≥ 9g/dL (women) or ≥ 11g/dL (men) (supportive transfusions will be allowed during induction and maintenance phases to maintain these levels)
- Platelets ≥ 100,000/mm3 (supportive transfusions will be allowed during induction and maintenance phases to maintain these levels)
- Serum Creatinine ≤ 1.5 x upper limit of normal (ULN)
- Serum Bilirubin ≤ 1.5 x ULN
- Serum AST/ALT ≤ 2.5 x ULN
- EKG documenting normal intervals.
- Fully recovered from any effects of major surgery, and be free of significant detectable infection.
- ECOG performance status of 0 or 1.
- Free of active brain metastases by contrast-enhanced CT/MRI scans within 4 weeks prior to starting the study drugs.
- Female patients of child bearing potential must have a negative pregnancy test (within 7 days from the time of randomization).
Exclusion Criteria:
- Serious illnesses, such as: cardiovascular disease (uncontrolled congestive heart failure, uncontrolled hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmia), bleeding disorders, symptomatic autoimmune diseases, severe obstructive or restrictive pulmonary diseases, uncontrolled endocrine disorders (hypothyroidism, hyperthyroidism and diabetes mellitus), retinopathy, active systemic infections, and inflammatory bowel disorders. This includes known HIV or AIDS-related illness, or active HBV and HCV.
- Prior therapy (except for adjuvant immunotherapy) with a BRAF and/or MEK and/or ERK inhibitors.
- Refractory nausea, vomiting, small bowel resection or any other gastrointestinal ailment that would preclude study drug absorption.
Cardiac abnormalities
- Mean QTc interval ≥ 480 msec at screening.
- Recent ACS/AMI - defined as within 24 weeks prior to screening.
- Recent PCI/PTCA - defined as within 24 weeks prior to screening.
- Recent malignant cardiac arrhythmias - all except sinus arrhythmia within 24 weeks prior to screening.
- Symptomatic heart failure - NYHA Class ≥ II symptoms.
- Active infection or antibiotics within one-week prior to study, including unexplained fever Any significant psychiatric disease, medical intervention, or other condition, which in the opinion of the principal investigator, could prevent adequate informed consent or compromise participation in the clinical trial.
- Systemic steroid or other immunosuppressive therapy within 4 weeks of starting the study.
- Lactating females or pregnant females.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Vemurafenib + IFNα-2b (10 MU/m2/d)
Vemurafenib + High-dose Interferon alfa-2b (10 MU/m2/d)
|
•Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects.
IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.
Andra namn:
Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal "BRAF" gene.
Andra namn:
|
Experimentell: Vemurafenib + IFNα-2b(15 MU/m2/d)
Vemurafenib + High-dose Interferon alfa-2b (15 MU/m2/d)
|
•Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects.
IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.
Andra namn:
Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal "BRAF" gene.
Andra namn:
|
Experimentell: Vemurafenib + IFNα-2b (20 MU/m2/d)
Vemurafenib + High-dose Interferon alfa-2b (20 MU/m2/d)
|
•Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects.
IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.
Andra namn:
Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal "BRAF" gene.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Participants with Adverse Events to determine Ph II dose
Tidsram: 12-24 months from study start
|
At each dose level, the number of patients experiencing Adverse Events over their course of treatment will be characterized by type of Adverse Event and grade using NCI CTCAE (v4.0), and by time of onset in relation to the first day of therapy.
|
12-24 months from study start
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Progression Free and overall survival (Efficacy)
Tidsram: 48 months
|
•Progression Free Survival will be evaluated at 6 months using the Kaplan-Meier method.
Overall Survival will be measured from the initial date of treatment to the recorded date of death, and analyzed similarly to Progression Free Survival.
Overall Survival will also be analyzed with the Kaplan-Meier method.
The complete response rate and partial response rate will be estimated by the proportion of patients with a best response respectively by RECIST criteria.
|
48 months
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Improve tumor STAT signaling
Tidsram: 48 months
|
Melanoma metastases removed from patients pretreatment, post-BRAFI alone and Post B-RAF+ will be analyzed for expression of IFNAR1 and immunologically relevant molecules such as HLA antigens, APM components and MA; these results will be correlated with T cell infiltration.
In addition the metastases will be tested for extent of melanoma cell proliferation and apoptosis.
|
48 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: John Kirkwood, MD, University of Pittsburgh Medical Center
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter histologisk typ
- Neoplasmer
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Neuroendokrina tumörer
- Nevi och melanom
- Melanom
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Enzyminhibitorer
- Antineoplastiska medel
- Immunologiska faktorer
- Proteinkinashämmare
- Interferoner
- Interferon-alfa
- Interferon alfa-2
- Vemurafenib
Andra studie-ID-nummer
- 12-107
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Melanom
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RekryteringMetastaserande melanom | Konjunktivalt melanom | Okulärt melanom | Ooperabelt melanom | Uveal melanom | Kutant melanom | Slemhinnemelanom | Iris melanom | Akralt melanom | Icke-kutant melanomFörenta staterna
-
MelanomaPRO, RussiaRekryteringMelanom | Melanom (hud) | Melanom Steg IV | Melanom stadium III | Melanom, stadium II | Melanom, Uveal | Melanom in Situ | Melanom, OkulärRyska Federationen
-
National Cancer Institute (NCI)AvslutadÅterkommande melanom | Steg IIIA melanom | Steg IIIB melanom | Steg IIIC melanom | Steg IIB melanom | Steg IIC melanom | Steg IA melanom | Steg IB melanom | Steg IIA melanomFörenta staterna
-
University of Southern CaliforniaNational Cancer Institute (NCI)AvslutadÅterkommande melanom | Steg IV melanom | Slemhinnemelanom | Ciliary Body och Choroid Melanom, Medium/Large Storlek | Ciliarkropp och koroid melanom, liten storlek | Iris melanom | Metastaserande intraokulärt melanom | Återkommande intraokulärt melanom | Steg IV Intraokulärt melanom | Steg IIIA melanom | Steg... och andra villkorFörenta staterna
-
Mayo ClinicNational Cancer Institute (NCI)AvslutadÅterkommande melanom | Steg IV melanom | Steg IIIA melanom | Steg IIIB melanom | Steg IIIC melanom | Steg IIB melanom | Steg IIC melanom | Steg IIA melanomFörenta staterna
-
BiocadRekryteringMelanom | Melanom (hud) | Melanom Steg IV | Melanom stadium III | Melanom Metastaserande | Melanom ooperabelt | Melanom AvanceratIndien, Ryska Federationen, Belarus
-
National Cancer Institute (NCI)AvslutadSteg IV melanom | Ciliary Body och Choroid Melanom, Medium/Large Storlek | Iris melanom | Steg IIIA melanom | Steg IIIB melanom | Steg IIIC melanom | Extraokulärt förlängningsmelanom | Steg IIB melanom | Steg IIC melanomFörenta staterna
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkAvslutadÅterkommande melanom | Steg IV melanom | Metastaserande intraokulärt melanom | Återkommande intraokulärt melanom | Steg IV Intraokulärt melanom | Steg IIIA melanom | Steg IIIB melanom | Steg IIIC melanom | Extraokulärt förlängningsmelanom | Steg IIIA Intraokulärt melanom | Steg IIIB Intraokulärt melanom | Steg...Förenta staterna
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RekryteringOoperabelt melanom | Kliniskt stadium III kutant melanom AJCC v8 | Melanom hos okänd primär | Patologiskt stadium IIIB kutant melanom AJCC v8 | Patologiskt stadium IIIC kutant melanom AJCC v8 | Patologiskt stadium IIID kutant melanom AJCC v8 | Kliniskt stadium IV kutant melanom AJCC v8 | Patologiskt... och andra villkorFörenta staterna
-
National Cancer Institute (NCI)AvslutadÅterkommande melanom | Steg IV melanom | Steg IIIA melanom | Steg IIIB melanom | Steg IIIC melanom | Akralt lentiginöst malignt melanomFörenta staterna
Kliniska prövningar på High-dose Interferon alfa-2b
-
Mongolian National University of Medical SciencesMongolian National Cancer CenterRekryteringHPV-infektion | Cervikal dysplasiMongoliet
-
Merck Sharp & Dohme LLCAvslutad
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)UpphängdHematopoetisk och lymfoid cellneoplasma | Malign fast neoplasma | Symtomatisk COVID-19-infektion Laboratorie-bekräftadFörenta staterna
-
Amsterdam UMC, location VUmcMerck Sharp & Dohme LLC; Novartis; Uppsala University HospitalAvslutadKronisk myeloid leukemiNederländerna, Danmark, Sverige, Finland, Norge
-
Emory UniversityBayerAvslutad
-
Digna Biotech S.L.AvslutadKronisk hepatit C-virusinfektion | Genotyp 1 | Behandlingserfarna patienter | ÅterfallSpanien
-
Mayo ClinicNational Cancer Institute (NCI)Aktiv, inte rekryterandePrimär myelofibros | Sekundär myelofibrosFörenta staterna
-
St. Jude Children's Research HospitalSchering-PloughAktiv, inte rekryterandeMalignt melanomFörenta staterna
-
Brooke Army Medical CenterT.R.U.E. Research FoundationAvslutad
-
Emory UniversityCURE Childhood Cancer, Inc.AvslutadJuvenila pilocytiska astrocytom | Optic Pathway GliomasFörenta staterna